lapatinib has been researched along with gemcitabine in 23 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (gemcitabine) | Trials (gemcitabine) | Recent Studies (post-2010) (gemcitabine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 12,523 | 3,208 | 6,923 |
| Protein | Taxonomy | lapatinib (IC50) | gemcitabine (IC50) |
|---|---|---|---|
| Chain A, DEOXYNUCLEOSIDE KINASE | Drosophila melanogaster (fruit fly) | 0.76 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 0.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Laurie, SA; Licitra, L | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Burtness, B | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Elzawawy, A | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| Drebin, JA; Pippin, JA; Singla, S | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Komoto, M; Murata, A; Nakata, B | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Couvreur, P; Denis, S; Guillaneuf, Y; Jacobs, M; Lazzari, G; Mougin, J; Mura, S; Nicolas, J; Vinciguerra, D; Zhu, C | 1 |
| Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D | 1 |
| Cao, J; Du, Y; Hu, X; Li, T; Liu, X; Tao, Z; Wang, B; Wang, L; Zhang, J; Zhu, Y | 1 |
5 review(s) available for lapatinib and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Her signaling in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
7 trial(s) available for lapatinib and gemcitabine
| Article | Year |
|---|---|
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
11 other study(ies) available for lapatinib and gemcitabine
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
The "win-win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Trastuzumab | 2009 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin | 2012 |
In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lapatinib; Pancreatic Neoplasms; Quinazolines; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity.
Topics: Breast Neoplasms; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Combinations; Drug Synergism; Female; Gemcitabine; Humans; Lapatinib; MCF-7 Cells; Nanoparticles; Polymerization; Prodrugs | 2019 |
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome | 2020 |
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
Topics: Annexin A6; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Exosomes; Gemcitabine; Humans; Lapatinib; Proteolysis; Triple Negative Breast Neoplasms; Ubiquitination | 2021 |